Clinical Trials Directory

Trials / Completed

CompletedNCT02680561

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to ADVAIR® DISKUS® in Patients With Persistent Asthma 4 Through 11 Years of Age

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc. · Industry
Sex
All
Age
4 Years – 11 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to characterize the pharmacokinetic profiles of fluticasone propionate and/or salmeterol when delivered as a single oral inhalation dose of Fp MDPI and FS MDPI.

Conditions

Interventions

TypeNameDescription
DRUGFluticasone Propionate MDPI
DRUGFluticasone Propionate/Salmeterol MDPI
DRUGFluticasone propionate/salmeterol

Timeline

Start date
2016-04-01
Primary completion
2016-06-01
Completion
2016-08-01
First posted
2016-02-11
Last updated
2021-11-09

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02680561. Inclusion in this directory is not an endorsement.